Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Inclusion Criteria

• •1. B-ALL patients with history of relapse, or MRD positive in the last bone marrow examination before allo-HSCT;
• •2. Age ≥16 years old and ≤ 65 years old when signing informed consent Form (ICF);
• •3. KPS \> 60 or ECOG 0-2;
• •4. The expected survival time is more than 3 months;
• •5. Complete remission (CR) after allo-HSCT with either myeloablative or non-myeloablative conditioning regimen determined by the investigator;
• •6. Reach the standard of hematopoietic reconstitution (neutrophil count
• •≥ 0.5×10\^9/L for 3 consecutive days without G-CSF application, platelet count ≥ 20×10\^9/L for 7 consecutive days without platelet transfusion, Hb ≥ 80 g /L without red blood cell transfusion); and neutrophil count ≥ 1.5×10\^9/L, platelet count ≥ 50×10\^9/L within 45 days after transplantation;
• •7. No central nervous system involvement or clinical symptoms after transplantation;
• •8. Those who have no serious functional damage to important organs of the body;
• •9. Fully understand and be informed of this study and sign the ICF; willing to follow and have the ability to complete all test procedures;
• •10. Females of childbearing age must afford a serum pregnancy test within 7 days before the first dose, and the result should be negative; female participants and their partners should agree to use effective contraception from signing the ICF until 6 months after the last dose.